GlassScriptPhysician profile
Harsha Ranganath
NPI 1013282243
$3,163.94
in general payments reported to CMS, 2019-2025
47 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $329 · 2021: $30.93 · 2022: $105 · 2024: $503 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.81 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $407.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $288.58 | 2019-2025 | |
| Janssen Biotech, INC. | $244.18 | 2019-2025 | Darzalex, Talvey, Rybrevant |
| Astellas Pharma US INC | $184.80 | 2019-2025 | Vyloy |
| Pfizer INC. | $182.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $133.12 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $127.26 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $123.70 | 2024-2025 | Reblozyl |
| Tempus Ai, INC | $116.25 | 2024 | |
| Lilly USA, LLC | $104.19 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Inari Medical, INC. | $98.32 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $97.20 | 2025 | |
| Genzyme Corporation | $92.82 | 2019-2025 | |
| Daiichi Sankyo INC. | $80.17 | 2020-2025 | Datroway, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $69.47 | 2019-2025 | Fruzaqla |
Show all 45 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsha Ranganath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.